Postchemotherapy retroperitoneal lymph node dissection for testis cancer.

The treatment of patients with metastatic testicular cancer is multimodal. Postchemotherapy retroperitoneal lymph node dissection is a technically demanding procedure that can benefit appropriately selected patients. In this article, we review postchemotherapy retroperitoneal lymph node dissection, including indications, technical updates, and the management and outcomes of patients who undergo surgery. Many aspects continue to evolve, and we review the evidence regarding current controversies in the field.

[1]  J. Droz,et al.  Long‐term oncological outcome after post‐chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour , 2010, BJU international.

[2]  E. Klein,et al.  Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. , 2010, Urologic oncology.

[3]  J. Richie,et al.  Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data , 2010, BJU international.

[4]  L. Einhorn,et al.  Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Einhorn,et al.  Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum α‐fetoprotein , 2009, BJU international.

[6]  E. Barret,et al.  Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor. , 2009, Journal of endourology.

[7]  Terukazu Nakamura,et al.  Post‐chemotherapy nerve‐sparing retroperitoneal lymph node dissection for advanced germ cell tumor , 2009, International journal of urology : official journal of the Japanese Urological Association.

[8]  C. Wood,et al.  Long‐term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection , 2009, Cancer.

[9]  A. Zelikovski,et al.  Vena caval reconstruction during postchemotherapy retroperitoneal lymph node dissection for metastatic germ cell tumor. , 2009, Urology.

[10]  W. Brenner,et al.  [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Spiess,et al.  Malignant transformation of testicular teratoma: a chemoresistant phenotype. , 2008, Urologic oncology.

[12]  G. Bartsch,et al.  Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. , 2008, The Journal of urology.

[13]  G. Bartsch,et al.  Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary? , 2008, BJU international.

[14]  T. Christmas,et al.  Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome , 2008, BJU international.

[15]  N. Clarke,et al.  Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  W. Brenner,et al.  The Role of Positron Emission Tomography in the Evaluation of Residual Masses After Chemotherapy for Advanced Stage Seminoma , 2008 .

[17]  S. Fosså,et al.  Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  R. Motzer,et al.  Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Spiess,et al.  Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. , 2007, Urology.

[20]  A. Stenzl,et al.  Post-chemotherapy laparoscopic retroperitoneal lymph-node dissection in testis cancer patients. , 2007, Journal of endourology.

[21]  R. Motzer,et al.  Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Christmas,et al.  Repeat retroperitoneal lymph‐node dissection after chemotherapy for metastatic testicular germ cell tumour , 2007, BJU international.

[23]  L. Einhorn,et al.  Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? , 2007, Cancer.

[24]  D. Vanel,et al.  Chemotherapy in patients with teratoma with malignant transformation. , 2007, European urology.

[25]  L. Einhorn,et al.  Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome. , 2007, The Urologic clinics of North America.

[26]  B. Carver,et al.  Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. , 2007, Urology.

[27]  L. Einhorn,et al.  Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery. , 2007, The Journal of urology.

[28]  P. Spiess,et al.  Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. , 2007, The Journal of urology.

[29]  R. Motzer,et al.  Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. V. Kondagunta,et al.  Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors , 2007, Cancer.

[31]  Yvonne Vergouwe,et al.  Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. , 2007, European urology.

[32]  L. Kavoussi,et al.  Postchemotherapy laparoscopic retroperitoneal lymph node dissection: evaluation of complications. , 2007, Urology.

[33]  L. Einhorn,et al.  Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Sheinfeld,et al.  Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. , 2006, The Journal of urology.

[35]  C. Wood,et al.  Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. , 2006, The Journal of urology.

[36]  R. Motzer,et al.  Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. , 2006, The Journal of urology.

[37]  O. Yossepowitch,et al.  Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection , 2006, BJU international.

[38]  Ewout W Steyerberg,et al.  Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. , 2006, European journal of cancer.

[39]  L. Einhorn,et al.  Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? , 2006, The Journal of urology.

[40]  P. Spiess,et al.  455: Malignant Transformation of Testicular Teratoma: A Chemoresistant Phenotype , 2006 .

[41]  L. Einhorn,et al.  Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  G. Janetschek,et al.  Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer. , 2005, Journal of endourology.

[43]  A. Scott,et al.  18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. , 2004, Urology.

[44]  W. Siegert,et al.  Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Tobias-Machado,et al.  Retroperitoneal lymphadenectomy by videolaparoscopic transperitoneal approach in patients with non-seminomatous testicular tumor. , 2004, International braz j urol : official journal of the Brazilian Society of Urology.

[46]  M. Koch,et al.  Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. , 2004, The Journal of urology.

[47]  R. Fimmers,et al.  Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. , 2004, The Journal of urology.

[48]  B. Leibovich,et al.  Histology in mixed germ cell tumors. Is there a favorite pairing? , 2004, The Journal of urology.

[49]  C. Bokemeyer,et al.  2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  G. Bartsch,et al.  Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. , 2004, Urology.

[51]  T. Miki,et al.  Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers , 2003, Cancer.

[52]  J. Bacik,et al.  Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. , 2003, Urology.

[53]  B. Leibovich,et al.  Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? , 2003, The Journal of urology.

[54]  C. Wood,et al.  Repeat retroperitoneal lymph node dissection for metastatic testis cancer. , 2003, The Journal of urology.

[55]  M. Bains,et al.  The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours , 2003, BJU international.

[56]  J. Habbema,et al.  External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients , 2003, British Journal of Cancer.

[57]  P. Biron,et al.  Management of post-chemotherapy residual masses in advanced seminoma. , 2002, The Journal of urology.

[58]  T. Miki,et al.  Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy , 2002, International journal of urology : official journal of the Japanese Urological Association.

[59]  L. Kavoussi,et al.  Laparoscopic retroperitoneal lymph node dissection after chemotherapy. , 2002, Urology.

[60]  D. Rosell,et al.  18F‐fluoro‐2‐deoxyglucose‐positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse , 2002, BJU international.

[61]  L. Kiemeney,et al.  The role of 18fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours , 2002, BJU international.

[62]  D. Dearnaley,et al.  Metastatic nonseminomatous germ cell tumors of the testis , 2002, Cancer.

[63]  S. Culine,et al.  Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Donohue,et al.  Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. , 2001, The Journal of urology.

[65]  P. Albers,et al.  Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. , 2000, The Journal of urology.

[66]  S. Lalka,et al.  Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. , 1998, Journal of vascular surgery.

[67]  L. Einhorn,et al.  Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. , 1998, Urology.

[68]  J. Ong,et al.  Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. , 1998, British journal of urology.

[69]  P. McGraw,et al.  Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology. , 1998, The Journal of urology.

[70]  J. Donohue,et al.  Integration of surgery and systemic therapy: results and principles of integration. , 1998, Seminars in urologic oncology.

[71]  J. Donohue,et al.  En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. , 1998, The Journal of urology.

[72]  A. Renshaw,et al.  Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases. , 1998, The Journal of urology.

[73]  R. Paterson,et al.  Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? , 1998, British journal of urology.

[74]  T. Ahlering,et al.  Vena caval resection for bulky metastatic germ cell tumors: an 18-year experience. , 1997, The Journal of urology.

[75]  L. Einhorn,et al.  Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Habbema,et al.  Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor , 1997, Cancer.

[77]  J. Donohue,et al.  Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. , 1996, The Journal of urology.

[78]  P. Alken,et al.  Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations. , 1996, The Journal of urology.

[79]  T. Ulbright,et al.  Teratoma in the Orchiectomy Specimen and Volume of Metastasis are Predictors of Retroperitoneal Teratoma in Post-Chemotherapy Nonseminomatous Testis Cancer , 1996 .

[80]  J. Donohue,et al.  Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. , 1996, The Journal of urology.

[81]  M. Mazumdar,et al.  Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  L. Einhorn,et al.  The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. , 1996, The Journal of urology.

[83]  M. Jewett,et al.  Metastatic testicular tumor requiring inferior vena cava resection. , 1996, Urology.

[84]  D. Skinner,et al.  En bloc aortic resection for bulky metastatic germ cell tumors. , 1995, The Journal of urology.

[85]  J P Donohue,et al.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  J. Baniel,et al.  Original Articles: Testis Cancer: Complications of Post-Chemotherapy Retroperitoneal Lymph Node Dissection , 1995 .

[87]  J. Baniel,et al.  Complications of post-chemotherapy retroperitoneal lymph node dissection. , 1995, The Journal of urology.

[88]  J. Donohue,et al.  Management of retroperitoneal recurrences. Seminoma and nonseminoma. , 1994, The Urologic clinics of North America.

[89]  T. Ulbright,et al.  Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  J. Thornhill,et al.  Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. , 1993, British journal of urology.

[91]  L. Einhorn,et al.  Surgical salvage of chemorefractory germ cell tumors. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  R. Motzer,et al.  Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. , 1992, The Journal of urology.

[93]  G. Chodak,et al.  Laparoscopic retroperitoneal lymph node dissection in a patient with stage 1 testicular carcinoma. , 1992, The Journal of urology.

[94]  S. Fosså,et al.  Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  D. Dearnaley,et al.  Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. , 1991, European journal of cancer.

[96]  T. Splinter,et al.  Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma. , 1991, The Journal of urology.

[97]  N. Geller,et al.  Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  S. Fosså,et al.  Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. , 1989, The Journal of urology.

[99]  P. Loehrer,et al.  Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  L. Weissbach,et al.  Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. , 1987, The Journal of urology.

[101]  L. Einhorn,et al.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.

[102]  K. Kopecky,et al.  Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. , 1987, The Journal of urology.

[103]  J. Donohue,et al.  Distribution of nodal metastases in nonseminomatous testis cancer. , 1982, The Journal of urology.

[104]  L. Einhorn,et al.  Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy. , 1982, The Journal of urology.

[105]  L. Einhorn.  Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. , 1981, Cancer research.

[106]  P. Albers,et al.  Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. , 2009, European urology.

[107]  A. Heidenreich,et al.  Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. , 2005, European urology.

[108]  A. Horwich,et al.  Initial chemotherapy for stage II testicular non-seminoma , 2004, World Journal of Urology.

[109]  J. Sheinfeld,et al.  Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. , 2004, Journal of Urology.

[110]  J. Habbema,et al.  Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  T. Ahlering,et al.  Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. , 1994, Urology.